查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886416

日光性角化症治療市場－全球產業規模、佔有率、趨勢、機會和預測，依治療方法、藥物類別、最終用戶、地區和競爭格局分類，2020-2030年預測

Actinic Keratosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Drug Class, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球光化性角化症治療市場規模將從2024年的69.2億美元成長到2030年的92.5億美元，複合年成長率為4.95%。全球光化性角化症（AK）治療市場涵蓋藥物介入（如外用藥物和光動力療法）以及手術切除等外科治療方法，所有這些方法都旨在治療主要由慢性紫外線照射引起的癌前皮膚病變。

市場概覽
預測期 2026-2030
市場規模：2024年 69.2億美元
市場規模：2030年 92.5億美元
複合年成長率：2025-2030年 4.95%
成長最快的細分市場 手術
最大的市場 北美洲

主要市場促進因素

全球光化性角化症治療市場主要受光化性角化症患者病率上升和全球人口老化的影響。光化性角化症發生率的增加直接擴大了需要診斷和治療的患者群體。

主要市場挑戰

熟練的皮膚科專家和合格的醫療保健人員持續短缺，嚴重阻礙了全球光化性角化病治療市場的發展。這種短缺直接限制了治療的普及，並導致患者治療的嚴重延誤。

主要市場趨勢

新型局部和全身療法的出現，顯著推動了全球光化性角化病治療市場的發展，這些療法引入了療效更佳、副作用更少、作用機制創新的先進藥物。這些新療法通常能夠彌補現有療法的不足，為皮膚科醫生提供更廣泛的選擇，從而製定更個人化的患者治療方案，並有可能提高疾病清除率。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球日光性角化症治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療方法（局部治療、手術、光動力療法）
    • 依藥物類別（核苷代謝抑制劑、非類固醇抗發炎藥、免疫反應調節劑、光增強劑、其他）
    • 按最終使用者（醫院和診所、門診中心、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美日光性角化症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲日光性角化症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區日光性角化症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東及非洲日光性角化症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲日光性角化症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球日光性角化症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Almirall SA
  • LEO Pharma A/S
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • GALDERMA SA
  • Ortho Dermatologics (Bausch Health Companies Inc.)
  • BIOFRONTERA AG
  • Hill Dermaceuticals, Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22286

The Global Actinic Keratosis Treatment Market will grow from USD 6.92 Billion in 2024 to USD 9.25 Billion by 2030 at a 4.95% CAGR. The global actinic keratosis (AK) treatment market encompasses pharmaceutical interventions, such as topical medications and photodynamic therapy, alongside procedural approaches like cryotherapy and surgical excision, all aimed at addressing precancerous skin lesions primarily induced by chronic ultraviolet exposure.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.92 Billion
Market Size 2030USD 9.25 Billion
CAGR 2025-20304.95%
Fastest Growing SegmentSurgery
Largest MarketNorth America

Key Market Drivers

The global actinic keratosis treatment market is significantly propelled by the rising prevalence of actinic keratosis and the aging global population. The increasing incidence of actinic keratosis directly expands the patient pool requiring diagnosis and therapeutic intervention. According to the British Journal of Dermatology, March 2024, in "Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis", the global prevalence rate for actinic keratosis is 14%, indicating a substantial disease burden worldwide.

Key Market Challenges

The persistent lack of skilled dermatology specialists and qualified healthcare providers significantly impedes the growth of the global actinic keratosis treatment market. This shortage directly limits treatment penetration and causes substantial delays in patient care. Across various regions, the inadequate availability of specialists means fewer individuals receive timely diagnosis and appropriate therapeutic interventions for precancerous skin lesions.

Key Market Trends

The emergence of novel topical and systemic therapies significantly drives the global actinic keratosis treatment market by introducing advanced agents with improved efficacy, reduced side effects, and innovative mechanisms of action. These new treatments often address limitations of existing options, providing dermatologists with a broader range of choices for tailored patient care and potentially higher clearance rates.

Key Market Players

  • Almirall S.A.
  • LEO Pharma A/S
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • GALDERMA SA
  • Ortho Dermatologics (Bausch Health Companies Inc.)
  • BIOFRONTERA AG
  • Hill Dermaceuticals, Inc.

Report Scope:

In this report, the Global Actinic Keratosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Actinic Keratosis Treatment Market, By Therapy:

  • Topical
  • Surgery
  • Photodynamic Therapy

Actinic Keratosis Treatment Market, By Drug Class:

  • Nucleoside metabolic inhibitor
  • NSAIDS
  • Immune response modifiers
  • Photoenhancers
  • Others

Actinic Keratosis Treatment Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Actinic Keratosis Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Actinic Keratosis Treatment Market.

Available Customizations:

Global Actinic Keratosis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Actinic Keratosis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Topical, Surgery, Photodynamic Therapy)
    • 5.2.2. By Drug Class (Nucleoside metabolic inhibitor, NSAIDS, Immune response modifiers, Photoenhancers, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Actinic Keratosis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Drug Class
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Actinic Keratosis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Actinic Keratosis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Drug Class
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Actinic Keratosis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Drug Class
        • 6.3.3.2.3. By End User

7. Europe Actinic Keratosis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Drug Class
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Actinic Keratosis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By End User
    • 7.3.2. France Actinic Keratosis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Actinic Keratosis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Actinic Keratosis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy
        • 7.3.4.2.2. By Drug Class
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Actinic Keratosis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy
        • 7.3.5.2.2. By Drug Class
        • 7.3.5.2.3. By End User

8. Asia Pacific Actinic Keratosis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Drug Class
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Actinic Keratosis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By End User
    • 8.3.2. India Actinic Keratosis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Actinic Keratosis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Actinic Keratosis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Drug Class
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Actinic Keratosis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Drug Class
        • 8.3.5.2.3. By End User

9. Middle East & Africa Actinic Keratosis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Drug Class
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Actinic Keratosis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Actinic Keratosis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Actinic Keratosis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By End User

10. South America Actinic Keratosis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Drug Class
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Actinic Keratosis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Drug Class
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Actinic Keratosis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Drug Class
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Actinic Keratosis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Drug Class
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Actinic Keratosis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Almirall S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. LEO Pharma A/S
  • 15.3. Sun Pharmaceutical Industries Ltd.
  • 15.4. Novartis AG
  • 15.5. GALDERMA SA
  • 15.6. Ortho Dermatologics (Bausch Health Companies Inc.)
  • 15.7. BIOFRONTERA AG
  • 15.8. Hill Dermaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer